Stepwise safety trial of a killed Leishmania vaccine in Iran.
Dowlati
Y
Y
Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Iran.
Ehsasi
S
S
Shidani
B
B
Bahar
K
K
D000293:Adolescent; D000328:Adult; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D007492:Iran; D018320:Leishmania major / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D016052:Protozoan Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D012449:Safety; D012882:Skin Tests; D014374:Tuberculin Test; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D000953:Antigens, Protozoan; D001500:BCG Vaccine; D016207:Cytokines; D010919:Placebos; D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated; C032127:leishmanin